Bioventus

Bioventus

Bioventus develops innovations in pain treatment, restorative therapies, and surgical solutions to help patients resume active lives. Learn more

Launch date
Employees
Market cap
CAD993m
Enterprise valuation
CAD1.5b (Public information from Sep 2024)
Durham North Carolina (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues321m431m512m512m562m598m639m
% growth(6 %)34 %19 %-10 %6 %7 %
EBITDA54.9m52.6m31.1m60.7m106m112m128m
% EBITDA margin17 %12 %6 %12 %19 %19 %20 %
Profit16.4m19.4m(159m)(156m)(9.5m)11.0m33.8m
% profit margin5 %4 %(31 %)(30 %)(2 %)2 %5 %
EV / revenue-2.7x1.1x1.4x1.8x1.5x1.3x
EV / EBITDA-22.3x17.6x11.4x9.7x8.2x6.7x
R&D budget11.2m19.0m25.9m13.4m---
R&D % of revenue3 %4 %5 %3 %---
  • Edit
DateInvestorsAmountRound

$118m

Late VC

$12.0m

Debt

N/A

-
N/A

N/A

IPO
*
N/A

$415m

Post IPO Debt
Total FundingCAD161m

Recent News about Bioventus

Edit
More about Bioventusinfo icon
Edit

Bioventus Inc., established in 2012 and headquartered in Durham, NC, is a global leader in developing biologics and medical devices aimed at active healing. The company specializes in products that promote bone healing and provide relief from osteoarthritis pain. Bioventus serves a diverse range of clients, including healthcare providers and patients seeking non-drug solutions for chronic pain and bone-related conditions. Operating in the medical technology market, Bioventus generates revenue through the sale of its innovative products, which are known for their safety, effectiveness, and ability to improve patient outcomes. In 2022, Bioventus products helped over 600,000 people regain active lifestyles. The company's business model focuses on continuous innovation and partnerships to enhance its product portfolio and market reach. Key products include orthobiologics, biologics, and the StimRouter, a device that delivers electrical pulses to target chronic peripheral nerve pain.

Keywords: biologics, bone healing, osteoarthritis, pain relief, medical devices, chronic pain, orthobiologics, active lifestyles, healthcare, innovation.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Bioventus

Edit
CartiHeal
ACQUISITION by Smith & Nephew Nov 2023
Misonix
ACQUISITION by Bioventus Oct 2021
Bioness
ACQUISITION by Bioventus Mar 2021
BioStructures
ACQUISITION by Bioventus Nov 2015